Cardiac Ablation Devices - Market Insights, Competitive Landscape, and Market Forecast - 2030

Cardiac Ablation Devices Market by Technology (Radiofrequency (RF) Ablation, Electrical Ablation, Cryoablation, Ultrasound Ablation, and Microwave Ablation), Product (Radiofrequency (RF) Ablators [Temperature-Controlled Radiofrequency Ablators, Fluid-Cooled Radiofrequency Ablators, and Robotic Catheter Manipulation Systems], Electrical Ablators [Argon Plasma/Beam Coagulators, and Irreversible Electroporation Systems], Cryoablation Devices [Tissue Contact Probes, and Others], Ultrasound Ablators [High-Intensity Focused Ultrasound Ablators, Ultrasound Ablation Systems, and Others], and Microwave Ablators [Microwave Thermotherapy Devices]), Application (Cardiac Rhythm Management, Open Surgery, and Others), End-User (Hospitals, Cardiac Centers, and Ambulatory Surgical Centers), and Geography (North America, Europe, Asia-Pacific, and Rest of the World) is expected to grow at a steady CAGR forecast till 2030 owing to the rising burden of cardiac diseases, increased adoption of minimally invasive procedures, increasing awareness and screening programs, and increase in product launches and approvals by key market players across the globe.

The cardiac ablation devices market was valued at USD 2.25 billion in 2023, growing at a CAGR of 12.77% during the forecast period from 2024 to 2030, to reach USD 4.63 billion by 2030. The demand for cardiac ablation devices is motivated by a rise in the prevalence of cardiovascular diseases like cardiac arrhythmia, atrial fibrillation, and stroke. Additionally, minimally invasive procedures like cardiac ablation are gaining traction due to their advantages over traditional open-heart surgeries. Patients prefer these procedures because they offer shorter recovery times, reduced hospital stays, and lower risks of complications such as infection and bleeding. Furthermore, the growing awareness about cardiac arrhythmias and advancements in diagnostic technologies have led to earlier detection through screening programs. As awareness increases among patients and healthcare providers alike, there is a corresponding rise in the number of cases diagnosed and treated. This trend not only expands the market for cardiac ablation devices but also supports timely intervention and better management of cardiac conditions, improving overall patient outcomes during the forecast period from 2024 to 2030.

Cardiac Ablation Devices Market Dynamics:

According to the World Heart Federation (2024), approximately 60 million population are affected by atrial fibrillation which is one of the most common types of irregular heartbeat, or arrhythmia. It can increase the risk of blood clots, heart failure, and stroke. Additionally, as per the same source people with atrial fibrillation are 5X times more likely to suffer a stroke.

Furthermore, according to the recent data and stats provided by the Australian Institute of Health and Welfare (2024), in 2021, more than 500,000 population were affected by atrial fibrillation.

According to the latest data published by the British Heart Foundation (2024), globally, around 56 million women and 45 million men are stroke survivors. It's estimated that at least 13 million people worldwide live with congenital heart disease, with potentially millions more undiagnosed.

The increase in stroke incidence can boost the market for cardiac ablation devices due to the strong link between atrial fibrillation (AFib) and stroke risk. AFib is a significant risk factor for stroke, as the irregular heart rhythm can lead to the formation of blood clots in the heart, which can then travel to the brain and cause a stroke. Additionally, the increase in (AFib) directly boosts the market for cardiac ablation devices as it is a minimally invasive procedure that targets and destroys the heart tissue causing the abnormal electrical signals, which is recognized for its efficacy in restoring normal rhythm, particularly in patients who do not respond well to medications. The growing AFib patient population leads to increased referrals for ablation procedures, driving up the adoption of advanced ablation devices hence escalating the overall market across the globe.

Moreover, companies are increasing their manufacturing of essential medical device products. For instance, in August 2022, Acutus Medical, Inc. announced its innovative suite of software upgrades, known collectively as AcQMap 8, which received FDA clearance and was awarded, CE Mark. AcQMap 8 introduces advanced new mapping algorithms into Acutus’ foundational technology, the AcQMap 3D imaging, and mapping system. These algorithms including AcQTrack™ and the SlowZone™ Locator (Composite Maps) are designed to quickly highlight regions of interest during the mapping and ablation of complex atrial arrhythmias, the treatment of which has been shown to significantly improve patient outcomes.

Thus, the factors mentioned above are likely to boost the market of cardiovascular imaging equipment during the forecasted period.

However, cardiac ablation carries risks such as bleeding, infection, and damage to blood vessels or the heart during the procedures, and stringent regulatory concerns for product approval may hinder the future market of cardiac ablation devices.

Cardiac Ablation Devices Market Segment Analysis:

Cardiac Ablation Devices Market by Technology (Radiofrequency (RF) Ablation, Electrical Ablation, Cryoablation, Ultrasound Ablation, and Microwave Ablation), Product (Radiofrequency (RF) Ablators [Temperature-Controlled Radiofrequency Ablators, Fluid-Cooled Radiofrequency Ablators, and Robotic Catheter Manipulation Systems], Electrical Ablators [Argon Plasma/Beam Coagulators, and Irreversible Electroporation Systems], Cryoablation Devices [Tissue Contact Probes, and Others], Ultrasound Ablators [High-Intensity Focused Ultrasound Ablators, Ultrasound Ablation Systems, and Others], and Microwave Ablators [Microwave Thermotherapy Devices]), Application (Cardiac Rhythm Management, Open Surgery, and Others), End-User (Hospitals, Cardiac Centers, and Ambulatory Surgical Centers), and Geography (North America, Europe, Asia-Pacific, and Rest of the World)

In the technology segment of the cardiac ablation devices market, Radiofrequency (RF) Ablation is projected to hold a considerable market share in 2023. Radiofrequency (RF) ablation is significantly boosting the market of cardiac ablation devices due to its established efficacy, safety profile, and versatility in treating various types of cardiac arrhythmias, particularly atrial fibrillation (AFib). RF ablation works by delivering high-frequency electrical energy through a catheter to create localized heat, which ablates (destroys) the abnormal heart tissue causing erratic electrical signals. This precision in targeting the source of arrhythmias has made RF ablation a preferred treatment option among cardiologists. The technology’s ability to produce durable lesions with minimal collateral damage to surrounding tissues has enhanced its appeal, leading to increased adoption in clinical practice. Furthermore, advancements in catheter design, such as the development of irrigated-tip catheters and contact force-sensing technology, have improved the safety and effectiveness of RF ablation procedures, reducing the risk of complications and improving patient outcomes.

Additionally, the ongoing technological advancements in Radiofrequency (RF) Ablation by the key market players are further propelling the market of the segment. For instance, in March 2023 Medtronic received CE Mark approval for its Affera™ Mapping and Ablation System. This system includes the Sphere-9™ Catheter and Affera™ Prism-1 Mapping Software, which combine pulsed field ablation (PFA), radiofrequency (RF), and high-density (HD) mapping. It treats atrial arrhythmias and offers real-time feedback with easy-to-use mapping and navigation software.

Therefore, owing to the above-mentioned factors, the Radiofrequency (RF) Ablation category is expected to generate considerable revenue thereby pushing the overall growth of the global cardiac ablation devices market during the forecast period.

North America is expected to dominate the overall Cardiac Ablation Devices market:

North America is expected to account for the highest proportion of the Cardiac Ablation Devices market in 2023, out of all regions. This can be ascribed to the increasing prevalence of cardiac diseases such as atrial fibrillation, strokes, and others, increased government initiatives coupled with increased awareness programs for cardiac disease, and the presence of key market players engaged in mergers, acquisitions, product launches, and other market activities across the region are expected to escalate the market of cardiac ablation devices.

According to the recent data provided by the Centre for Disease Control and Prevention (2024), in 2022, approximately 4.9% of adults have been diagnosed with coronary heart disease.

Additionally, as per the recent data provided by the Centre for Disease Control and Prevention (2024), approximately 12.1 million population in the United States will have atrial fibrillation by 2023.

Additionally, as per the same source each year, over 795,000 individuals in the United States experience a stroke. Of these, approximately 610,000 are first-time or new strokes. Nearly 185,000 strokes, accounting for almost 1 in 4, occur in people who have already had a stroke.

Cardiac ablation, particularly with advanced technologies like radiofrequency (RF) and pulsed-field ablation (PFA), offers a minimally invasive and highly effective solution for restoring normal heart rhythm and reducing stroke risk. This demand is further fueled by improvements in ablation technology, such as better mapping and navigation systems, which enhance procedure efficacy and safety thereby boosting the overall market of cardiac ablation across the region.

Additionally, the awareness programs in the United States aimed at addressing cardiac diseases focus on education, prevention, and early detection also boost the market of Cardiac Ablation Devices across the region as public awareness campaigns educate individuals about the importance of regular screenings and preventive measures. For example, February is designated as American Heart Month, during which various organizations, including the American Heart Association (AHA) and the Centers for Disease Control and Prevention (CDC), promote awareness through campaigns, events, and educational materials. These efforts emphasize the importance of heart health, risk factors, and preventive measures.

Furthermore, the rising number of product development activities for cardiac ablation devices in the region is further going to assist in the regional market growth. For example, in February 2021, the US FDA approved Medtronic’s DiamondTemp irrigated ablation catheter which is intended for the treatment of patients with recurrent atrial fibrillation that has not responded to drug therapies.

Therefore, the above-mentioned factors are expected to bolster the growth of the cardiac ablation devices market in North America during the forecast period.

Cardiac Ablation Devices Market Key Players:

Some of the key market players operating in the Cardiac Ablation Devices market include Abbott Laboratories, Boston Scientific Corporation, Avanos Medical, Inc., Auris Health, Inc., Olympus, CONMED Corporation, ERBE ELEKTROMEDIZIN GMBH, AngioDynamics, Medtronic plc., AtriCure, Inc., Biosense Webster, Inc., Teleflex Incorporated, St. Jude Medical Inc., Lepu Medical Technology(Beijing)Co., Ltd., MicroPort Scientific Corporation, and others.

Recent Developmental Activities in the Cardiac Ablation Devices Market:

• In January 2024, Boston Scientific Corporation announced that it received FDA approval for the FARAPULSE™ Pulsed Field Ablation (PFA) System. The system is used to isolate pulmonary veins in treating drug-resistant, paroxysmal atrial fibrillation (AF) and offers a new alternative to traditional thermal ablation treatments.
• In August 2023, Biosense Webster, Inc., part of Johnson & Johnson MedTech, announced that several products in its cardiac ablation portfolio received FDA approval for a zero fluoroscopy workflow. Approved products include the THERMOCOOL SMARTTOUCH™ SF and SMARTTOUCH™ Catheters, CARTO® VIZIGO® Bi-Directional guiding sheath, PENTARAY® NAV ECO high-density mapping catheter, DECANAV® mapping catheters, and Webster® CS Catheter.
• In April 2023, The Ottawa Heart Institute launched the Canadian commercial release of QDOT MICRO®, the world's first very high-power, short-duration ablation catheter.
• In August 2022, Acutus Medical announced that its suite of new algorithms for the mapping and ablation of complex atrial arrhythmias received FDA clearance and CE mark approval.
• In June 2022, The FDA granted a new indication to a cryoballoon ablation catheter that allows it to be used as a first-line treatment for atrial fibrillation, before antiarrhythmic drugs. Until the new indication for the catheter (Arctic Front Advance, Medtronic), catheter ablation was approved only for use in patients with atrial fibrillation who had failed antiarrhythmic drug therapy.

Key Takeaways From the Cardiac Ablation Devices Market Report Study:

• Market size analysis for current cardiac ablation devices size (2023), and market forecast for 6 years (2024 to 2030)
• Top key product/technology developments, mergers, acquisitions, partnerships, and joint ventures happened over the last 3 years
• Key companies dominating the cardiac ablation devices market.
• Various opportunities available for the other competitors in the cardiac ablation devices market space.
• What are the top-performing segments in 2023? How these segments will perform in 2030?
• Which are the top-performing regions and countries in the current cardiac ablation devices market scenario?
• Which are the regions and countries where companies should have concentrated on opportunities for cardiac ablation devices market growth in the coming future?

Target Audience who can be Benefited From This Cardiac Ablation Devices Market Report Study:

• Cardiac ablation devices product providers
• Research organizations and consulting companies
• Cardiac ablation devices -related organizations, associations, forums, and other alliances
• Government and corporate offices
• Start-up companies, venture capitalists, and private equity firms
• Distributors and traders dealing in cardiac ablation devices
• Various end-users who want to know more about the cardiac ablation devices market and the latest technological developments in the cardiac ablation devices market.

Frequently Asked Questions for the Cardiac Ablation Devices Market:

1. What are cardiac ablation devices?

Cardiac ablation devices are medical devices that can correct cardiac arrhythmias by scarring tiny regions of the heart. Cardiac arrhythmias arise when there is a deficiency of the electrical impulses that regulate the heartbeats. As a consequence, heartbeats are irregular and can lead to stroke or heart failure if left untreated, and are one of the main causes of death.

2. What is the market for cardiac ablation devices?

The cardiac ablation devices market was valued at USD 2.25 billion in 2023, growing at a CAGR of 12.77% during the forecast period from 2024 to 2030, to reach USD 4.63 billion by 2030.

3. What are the drivers for the cardiac ablation devices market?

The demand for cardiac ablation devices is motivated by a rise in the prevalence of cardiovascular diseases like cardiac arrhythmia, atrial fibrillation, and stroke. Additionally, minimally invasive procedures like cardiac ablation are gaining traction due to their advantages over traditional open-heart surgeries. Patients prefer these procedures because they offer shorter recovery times, reduced hospital stays, and lower risks of complications such as infection and bleeding. Furthermore, the growing awareness about cardiac arrhythmias and advancements in diagnostic technologies have led to earlier detection through screening programs. As awareness increases among patients and healthcare providers alike, there is a corresponding rise in the number of cases diagnosed and treated. This trend not only expands the market for cardiac ablation devices but also supports timely intervention and better management of cardiac conditions, improving overall patient outcomes during the forecast period from 2024 to 2030.

4. Who are the key players operating in the cardiac ablation devices market?

Some of the key market players operating in the Cardiac Ablation Devices market include Abbott Laboratories, Boston Scientific Corporation, Avanos Medical, Inc., Auris Health, Inc., Olympus, CONMED Corporation, ERBE ELEKTROMEDIZIN GMBH, AngioDynamics, Medtronic plc., AtriCure, Inc., Biosense Webster, Inc., Teleflex Incorporated, St. Jude Medical Inc., Lepu Medical Technology(Beijing)Co., Ltd., MicroPort Scientific Corporation, and others.

5. Which region has the highest share in the cardiac ablation devices market?

North America is expected to account for the highest proportion of the Cardiac Ablation Devices market in 2023, out of all regions. This can be ascribed to the increasing prevalence of cardiac diseases such as atrial fibrillation, strokes, and others, increased government initiatives coupled with increased awareness programs for cardiac disease, and the presence of key market players engaged in mergers, acquisitions, product launches, and other market activities across the region are expected to escalate the market of cardiac ablation devices.


This product will be delivered within 2 business days.